Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

Checkmab S.r.l.600 enrolled

Overview

The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Healthy Donors

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * blood donors * age of 18 years or more * able to sign informed consent Exclusion Criteria: * age below 18 years * Positive for HIV, HCV, HBV * not suitable for blood donation * not able to understand or sign informed consent

Locations (1)

S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

RECRUITING

Outcomes

Primary Outcomes

Validation of molecular targets for immunotherapy

Time frame: 04.2023-06.2026

Selection of therapeutic antibodies

Time frame: 04.2023-06.2026

Secondary Outcomes

Set up of immunological assays to adress monoclonal antibodies mechanism of action

Time frame: 04.2023-06.2026

Central Contacts

Renata M Grifantini, PhD

CONTACT

0039 00660220 renata.grifantini@checkmab.eu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.